Want to see KRMD full AI Analyst Report?
Top Page
REPRO-MED Systems
(NASDAQ:KRMD)
Select Model
Select Model
Rating:60Neutral
Price Target:
$4.50
▲(17.49% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by improving financial fundamentals (rapid revenue growth, stable gross margins, positive TTM operating/free cash flow, and low leverage) and a positive earnings-call read-through (raised gross-margin guidance and reiterated positive adjusted EBITDA). These positives are tempered by still-negative profitability, limited valuation support due to a negative P/E and no dividend yield, and mostly neutral technical indicators.
Positive Factors
Recurring installed base
A roughly 60,000‑patient installed base and consumable-driven model create durable, repeatable revenue. Consumable reorders tied to ongoing therapy generate predictable demand, reduce customer acquisition frequency, and increase lifetime value per placement over multiple years.
Negative Factors
Ongoing net losses
Despite margin and cash improvements, the company remains unprofitable on a TTM basis with negative ROE. Continued net losses mean equity value has yet to compound, requiring persistent margin expansion and scale to translate positive cash flow into durable shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring installed base
A roughly 60,000‑patient installed base and consumable-driven model create durable, repeatable revenue. Consumable reorders tied to ongoing therapy generate predictable demand, reduce customer acquisition frequency, and increase lifetime value per placement over multiple years.
Read all positive factors
REPRO-MED Systems (KRMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$153.52M
Dividend YieldN/A
Average Volume (3M)198.68K
Price to Earnings (P/E)―
Beta (1Y)0.87
Revenue Growth22.41%
EPS Growth60.02%
CountryUS
Employees73
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.04
Shares Outstanding46,171,900
10 Day Avg. Volume166,933
30 Day Avg. Volume198,682
Financial Highlights & Ratios
PEG Ratio1.81
Price to Book (P/B)15.74
Price to Sales (P/S)6.52
P/FCF Ratio-570.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.60Price Target Upside72.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$48.04M
REPRO-MED Systems Business Overview & Revenue Model
Company Description
KORU Medical Systems, Inc. is dedicated to the development, manufacturing, and commercialization of mobile medical devices, primarily serving the ambulatory infusion market across both the United States and international territories. The company's...
How the Company Makes Money
KRMD generates revenue primarily by selling its infusion therapy products to healthcare providers and distribution partners. A key component of its model is a recurring “razor-and-blades” dynamic: the company sells durable or semi-durable pump har...
REPRO-MED Systems Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call presented multiple meaningful operational and financial achievements — record quarterly revenue ($12M, +18% YoY), strong domestic (+12% YoY) and international (+59% YoY) performance, margin expansion (65.1% in Q2) and return to positive net income and adjusted EBITDA — alongside strategic progress (tech acquisition, Freedom360 development, active 510(k) for deferoxamine). Offsetting items include near-term timing and execution risks: a moderated international ramp pushing some revenue into 2027, the U.S. Phesgo withdrawal delaying oncology entry, variability in pharma services (–35% YoY), and multi-year timelines for connected technology and regulatory approvals. Overall, highlights substantially outweigh the lowlights, though some growth is timing-dependent.Positive Updates
Record Quarterly Revenue and Year-to-Date Growth
Q2 revenue of $12.0M, up 18% year-over-year for the quarter; first half revenue growth of 20% year-to-date.
Negative Updates
Pharma Services Revenue Decline and Variability
Pharma services revenue of $0.6M in Q2, down 35% year-over-year, driven by customer order timing and inherent quarter-to-quarter variability in clinical trial ordering.
Read all updates
Q2-2026 Updates
Positive
Negative
Record Quarterly Revenue and Year-to-Date Growth
Q2 revenue of $12.0M, up 18% year-over-year for the quarter; first half revenue growth of 20% year-to-date.
Read all positive updates
Company Guidance
Management narrowed full‑year revenue guidance to $47.5–$48.5 million and reiterated an expectation of positive adjusted EBITDA for the full year, while raising gross‑margin guidance to 62%–64% (up from 61%–63%) after delivering Q2 gross margin of 65.1% (vs. 63.5% LY, +160 bps) and H1 gross margin of 60.3% (up 20 bps). They now expect year‑end cash to be greater than $7.5 million (Q2 cash was $8.3M with only $0.5M net cash usage in the quarter), noted access to an unused $10 million credit facility (which was not drawn to fund the connected‑technology asset), reported H1 adjusted EBITDA of $0.9M and H1 revenue growth of 20% (Q2 revenue $12.0M, +18% YoY), and said some international prefilled‑syringe revenue is being pushed into 2027 while supplier contract extensions further de‑risk the bottom end of margin guidance.REPRO-MED Systems Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.11M | 41.13M | 33.65M | 28.52M | 27.90M | 23.49M |
| Gross Profit | 27.96M | 25.60M | 21.33M | 16.71M | 15.37M | 13.77M |
| EBITDA | -1.02M | -1.81M | -5.29M | -8.90M | -10.09M | -5.90M |
| Net Income | -1.82M | -2.64M | -6.07M | -13.74M | -8.66M | -4.56M |
Balance Sheet | ||||||
| Total Assets | 27.96M | 28.20M | 27.22M | 28.46M | 42.33M | 41.29M |
| Cash, Cash Equivalents and Short-Term Investments | 8.29M | 8.87M | 9.58M | 11.48M | 17.41M | 25.33M |
| Total Debt | 3.24M | 3.50M | 3.99M | 4.45M | 4.93M | 604.14K |
| Total Liabilities | 9.91M | 11.15M | 10.40M | 8.11M | 11.01M | 4.79M |
| Stockholders Equity | 18.05M | 17.05M | 16.81M | 20.35M | 31.33M | 36.50M |
Cash Flow | ||||||
| Free Cash Flow | 263.47K | -470.11K | -1.62M | -5.71M | -8.21M | -4.69M |
| Operating Cash Flow | 1.39M | 462.40K | -319.72K | -4.89M | -5.40M | -4.32M |
| Investing Cash Flow | -1.14M | -949.79K | -1.33M | -814.60K | -2.80M | -366.17K |
| Financing Cash Flow | -16.61K | -221.35K | -248.53K | -218.87K | 279.49K | 2.71M |
REPRO-MED Systems Technical Analysis
Negative
3.83
Price Trends
4.04
Negative
4.10
Negative
4.57
Negative
Market Momentum
-0.20
Positive
30.33
Neutral
12.87
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Negative. The current price of 3.83 is below the 20-day moving average (MA) of 3.86, below the 50-day MA of 4.04, and below the 200-day MA of 4.57, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 30.33 is Neutral, neither overbought nor oversold. The STOCH value of 12.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KRMD.
REPRO-MED Systems Risk Analysis
REPRO-MED Systems disclosed 52 risk factors in its most recent earnings report. REPRO-MED Systems reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
REPRO-MED Systems Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $229.55M | 22.05 | 8.74% | 1.84% | -7.00% | -12.28% | |
69 Neutral | $248.57M | 29.19 | 14.81% | ― | 2.47% | 75.23% | |
60 Neutral | $153.52M | -86.73 | -10.63% | ― | 22.41% | 60.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $277.25M | -5.57 | -21.50% | ― | -18.86% | -0.63% |
* Healthcare Sector Average
KRMD
REPRO-MED Systems
3.40
-0.77
-18.47%
INFU
InfuSystem Holdings
12.27
2.64
27.41%
OSUR
Orasure Technologies
3.84
1.08
39.13%
UTMD
Utah Medical Products
71.00
16.61
30.53%
MBOT
Microbot Medical
1.55
-1.54
-49.84%
REPRO-MED Systems Corporate Events
Business Operations and Strategy
KORU Medical Amends Long-Term Manufacturing and Supply Agreement
Neutral
Jun 30, 2026
On June 24, 2026, KORU Medical Systems, Inc. amended its manufacturing and supply agreement with Command Medical Products, LLC, which produces its subassemblies, needle sets and tubing products. The revised contract extends the initial term to Dec...
Executive/Board ChangesShareholder Meetings
REPRO-MED Shareholders Back Board, Governance and Incentive Plan
Positive
May 21, 2026
REPRO‑MED Systems, a medical device company focused on home infusion therapies, held its 2026 Annual Meeting of Shareholders on May 19, 2026, with 36,678,784 shares voted. Shareholders elected all seven director nominees, including R. John F...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.